CRO

Frontage picks up two U.S. plants from Sun Pharma

Pennsylvania-based Frontage Labs is picking up two manufacturing facilities from India’s Sun Pharma for its newly launched affiliate CDMO, Frontida BioPharm. The terms of the deal were not disclosed.

Frontida will acquire Sun Pharma’s oral solid dosage manufacturing plants in Aurora, IL, and Philadelphia, as well as 15 related pharmaceutical products. Sun is selling the plants in a bid to consolidate its manufacturing facilities following its acquisition of Ranbaxy Labs.

As part of the deal, Frontida will continue manufacturing some Sun Pharma products at the sites, and offer employment to the existing production, quality and administrative staff. It will also develop and manufacture the 15 acquired products for commercial partners to distribute.

“The sites have experienced staff and state-of-art facilities and equipment that will serve as a foundation to Frontida’s launch of Contract Development and Manufacturing (‘CDMO’) services, said Song Li, Frontage CEO. “Frontida’s CDMO services will complement the high quality development services offered by Frontage Laboratories and provide our long-term clients a trusted partner for product manufacturing and commercial support.”

Last October, the CRO added 10,000 square feet to its Exton, PA, facility, doubling its bioanalytical lab capacity in the U.S. and adding 21 jobs. And in July, it acquired Somerset, NJ’s BDM Consulting, augmenting its full-service drug and medical device development services.

- here's the Frontida statement

Related Articles:
CRO Frontage gets into agrochemicals with new service offering
Frontage doubles its bioanalytics space